

# Pharmacy Utilization Meeting

September 30, 2022

## Attendees

Linda Coyle (IMS)  
Jennifer Stevens (IMS)  
David Angelaszek (IMS) – absent  
Chuck May (IMS) – absent  
Emily Carver (IMS)  
Kevin Ward (Georgia)  
Randi Rycroft (Idaho) – absent  
Serban Negoita (NCI)  
Peggy Adamo (NCI)  
Marina Matatova (NCI)  
Nadia Howlader (NCI) – absent  
Jennifer Hafterson (Seattle)  
Tiffany Janes (Seattle)  
Kaitlin Akif (NCI)

- We continued our discussion on claims prior to dx.
  - **Action:** Emily will send Serban a list of drugs prescribed prior to dx by modality that are listed as being exclusive oncologic agents. Use all registries. He will consult with colleagues to discuss how to proceed/interpret what we're seeing.
- Kevin requested to see a distribution of pharm\_flag x registry to give him a sense of coverage by registry.
  - **Action:** Emily will generate these results for the next meeting.
- The cumulative duration and quantity variables should have 2 versions: all claims after dx and only claims w/in 1 year after dx.
- There was lots of discussion about the labels that are being assigned to the fields. Emily will work on implementing what we discussed, which includes using the term first course to refer to the drug's on Lois's list and FCOT when the 1 year time restriction is imposed.